pKLD-CAG-DYSF-CFL
(Plasmid
#131457)
-
PurposeEncodes Dysferlin protein (Therapeutic gene) along with Follistatin protein to cure LGMD2B along with luciferase enzyme for in vivo live imaging
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 131457 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepKLD
- Total vector size (bp) 16156
-
Vector typeMammalian Expression, Bacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Addgene NGS identified two point mutations: R15C (in DYSF) and Q2579H (in CFL)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pKLD-CAG-DYSF-CFL was a gift from Michele Calos (Addgene plasmid # 131457 ; http://n2t.net/addgene:131457 ; RRID:Addgene_131457) -
For your References section:
Plasmid-Mediated Gene Therapy in Mouse Models of Limb Girdle Muscular Dystrophy. Guha TK, Pichavant C, Calos MP. Mol Ther Methods Clin Dev. 2019 Oct 14;15:294-304. doi: 10.1016/j.omtm.2019.10.002. eCollection 2019 Dec 13. 10.1016/j.omtm.2019.10.002 PubMed 31890729